Search research articles
Contact Us
Filters
Showing results (31-40 of 36) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 36 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2020
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
Caicun Zhou, Yina Wang, Jun Zhao, et al.
CA: a Cancer Journal for Clinicians
|
November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Lingying Wu, Jing Wang, Qingshui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer
Ning Li, Hualei Bu, Jihong Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
Lingfang Xia, Keqiang Zhang, Ying Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2022
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Ning Li, Youzhong Zhang, Jing Wang, et al.
The Lancet. Oncology
|
November 27, 2025
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
Huiping Li, Jieqiong Liu, Quchang Ouyang, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 36) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 36 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2020
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
Caicun Zhou, Yina Wang, Jun Zhao, et al.
CA: a Cancer Journal for Clinicians
|
November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Lingying Wu, Jing Wang, Qingshui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer
Ning Li, Hualei Bu, Jihong Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
Lingfang Xia, Keqiang Zhang, Ying Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2022
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Ning Li, Youzhong Zhang, Jing Wang, et al.
The Lancet. Oncology
|
November 27, 2025
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
Huiping Li, Jieqiong Liu, Quchang Ouyang, et al.
Page
of 4